KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Invested Capital (2016 - 2025)

Sarepta Therapeutics has reported Invested Capital over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • For Q4 2025, Invested Capital fell 56.66% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 56.66%, while the annual FY2025 figure was $1.2 billion, 56.66% down from the prior year.
  • Invested Capital for Q4 2025 was $1.2 billion at Sarepta Therapeutics, down from $1.4 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $2.7 billion in Q4 2024 and troughed at $1.0 billion in Q3 2021.
  • A 5-year average of $1.7 billion and a median of $1.7 billion in 2021 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: skyrocketed 97.1% in 2022 and later crashed 56.66% in 2025.
  • Year by year, Invested Capital stood at $1.5 billion in 2021, then grew by 29.33% to $1.9 billion in 2022, then grew by 8.71% to $2.1 billion in 2023, then increased by 27.06% to $2.7 billion in 2024, then crashed by 56.66% to $1.2 billion in 2025.
  • Business Quant data shows Invested Capital for SRPT at $1.2 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.4 billion in Q2 2025.